Purpose: The Prostate Cancer Prevention Trial reported that 15% of men with a prostate specific antigen less than 4 ng/ml and a normal digital rectal examination have biopsy detectable prostate cancer. However, limited published data describe the tumor features of prostate cancer detected at low prostate specific antigen levels (less than 2.5 ng/ml).
Materials And Methods: A total of 1,278 men underwent radical retropubic prostatectomy by 1 surgeon between 2003 and 2008. We describe the clinicopathological features of 77 patients with a preoperative prostate specific antigen of less than 2.5 ng/ml.
Results: Of the men with a low prostate specific antigen (less than 2.5 ng/ml) tumor 51 (66%) had findings suspicious for prostate cancer on digital rectal examination. Indications for prostate biopsy in the remainder of men included an increased prostate specific antigen velocity, hematospermia and abnormal transrectal ultrasound findings. Prostate cancer was detected at transurethral resection of the prostate in the remaining 8% of men. Despite having a low prostate specific antigen at diagnosis 8 (10.4%) and 20 (26%) men, respectively, had biopsy and radical retropubic prostatectomy Gleason grade 7 disease or greater, while 7 (9%) and 6 (7.8%), respectively, had extracapsular tumor extension or positive surgical margins. Compared to men with a normal digital rectal examination mean tumor volume was significantly higher in those with a suspicious digital rectal examination (3.3 vs 1.7 cc, p = 0.018).
Conclusions: Despite having a prostate specific antigen of less than 2.5 ng/ml at diagnosis, a considerable proportion of men had aggressive pathological features at radical retropubic prostatectomy. Digital rectal examination remains an important component of early prostate cancer detection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155762 | PMC |
http://dx.doi.org/10.1016/j.juro.2009.01.102 | DOI Listing |
Here we report results of a phase 1 multi-institutional, open-label, dose-escalation trial (NCT02744287) of BPX-601, an investigational autologous PSCA-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients with metastatic pancreatic (mPDAC) or castration-resistant prostate cancer (mCRPC). Primary objectives were to evaluate safety and tolerability and determine the recommended phase 2 dose/schedule (RP2D). Secondary objectives included the assessment of efficacy and characterization of the pharmacokinetics of rimiducid.
View Article and Find Full Text PDFWorld J Surg Oncol
December 2024
Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: To assess the clinical utility of PCA3 in the diagnostic accuracy, the correlation between PCA3 and biopsy or pathological characteristics and the performance of PCA3 to reduce the unnecessary biopsies in Chinese population.
Methods: A prospective study including patients with indication of prostate biopsies from 4 centers was conducted. All patients underwent PCA3 urine tests and prostate biopsies.
BMC Med Imaging
December 2024
Department of MRI, Xinxiang Central Hospital (The Fourth Clinical College of Xinxiang Medical University), 56 Jinsui Road, Xinxiang, Henan, 453000, China.
Background: To develop and validate an interpretable machine learning model based on intratumoral and peritumoral radiomics combined with clinicoradiological features and metabolic information from magnetic resonance spectroscopy (MRS), to predict clinically significant prostate cancer (csPCa, Gleason score ≥ 3 + 4) and avoid unnecessary biopsies.
Methods: This study retrospectively analyzed 350 patients with suspicious prostate lesions from our institution who underwent 3.0 Tesla multiparametric magnetic resonance imaging (mpMRI) prior to biopsy (training set, n = 191, testing set, n = 83, and a temporal validation set, n = 76).
Biosens Bioelectron
December 2024
Cnam, SATIE Laboratory, UMR, CNRS 8029, 292 rue Saint Martin, 75003, Paris, France. Electronic address:
This study aims to demonstrate that redox couples, regardless of their electrical charges, are unnecessary for detecting and quantifying electroactive proteins using an electrochemical sensor functionalized with a molecularly imprinted polymer. Our approach involved designing a polydopamine imprinted biosensor for detecting bovine serum albumin as the model protein. Electrochemical measurements were conducted in a phosphate-buffered solution (PBS) and solutions containing the negatively charged hexacyanoferrate, the neutral ferrocene, or the positively charged hexaammineruthenium (III) probes.
View Article and Find Full Text PDFClin Radiol
December 2024
Department of Radiology, The Second Affiliated Hospital of Nanjing Medical University, Nan Jing, PR China. Electronic address:
Aim: To evaluate the impact of different b-value combinations on synthetic diffusion-weighted imaging (sDWI) and determine the sDWI with an optimal b-value combination for prostatic cancer (PCa) diagnosis.
Material And Methods: A retrospective analysis of 68 patients with abnormal prostate-specific antigen (PSA) was conducted. The sDWI images with b value of 1500 s/mm were separately reconstructed by the following five b-value combinations: b=0, 200s/mm (sDWI); b=600, 800s/mm (sDWI); b=0, 600s/mm (sDWI); b=200, 800s/mm sDWI); b=0, 800s/mm (sDWI).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!